REPROCELL Europe’s CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research
03 March 2017
REPROCELL Europe’s CEO, Dr David Bunton presented at the recent NC3Rs meeting on the use of human tissues in cancer research. The conference considered the potential for human tissue models to help reduce clinical drug attrition and provide...
REPROCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan
14 February 2017
REPROCELL Inc. (Japan)’s CEO Dr Chikafumi Yokoyama had the honour of meeting with Fiona Hyslop, Cabinet Secretary for Culture, Tourism and External Affairs for the Scottish Government, during her visit to the Scottish Enterprise Tokyo offic...
Scottish Enterprise Association Honours REPROCELL with Annual Awards Nomination
07 February 2017
Scotland’s Life Sciences Dinner was held on 2nd February 2017 at the National Museum of Scotland. The event was attended by CEO and Chairman of REPROCELL Inc, Dr Chikafumi Yokoyama, as well as senior management members of REPROCELL Europe L...
Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy
11 November 2016
Company: REPROCELL, Inc. (JASDAQ Company code: 4978) Representative: CEO Chikafumi Yokoyama Inquiries: CFO Daisuke Usui (TEL.045-475-3887) Today, REPROCELL Inc. (“REPROCELL”) has entered into a partnership with Steminent Biotherapeutics Inc...
Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins
13 May 2016
Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD)...
Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase
21 April 2016
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease. Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopt...
REPROCELL acquires Biopta to expand its drug discovery services
25 November 2015
The Japanese regenerative medicine company REPROCELL Inc. has announced the acquisition of the Scottish life sciences company, Biopta. The acquisition of Biopta and its US subsidiary, Biopta Inc. is expected to complete on the 10th of Decem...
Biopta co-authors research in the European Respiratory Journal
18 November 2015
The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society. This abstract describes the biological mechanisms by whic...
REPROCELL announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by REPROCELL and others
19 October 2015
Company: REPROCELL, Inc. (JASDAQ Company code: 4978) Representative: Chikafumi Yokoyama, PhD Contact: info-emea@reprocell.com We are pleased to announce that a research report on “3D Skin Model Construction,” submitted by our corporate grou...
New paper demonstrates formation of spontaneously active neuronal networks by stem cell derived neurons in 3D Alvetex Scaffold culture system
05 March 2015
A recently published paper by Imogen Smith et al. demonstrates the use of the Alvetex platform to culture 3D differentiated human neural stem cells. The cells formed spontaneously active, functional neuronal networks which were not seen in ...